Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option
-
Maxim Group Upgrades Atlantic Tele-Network (ATNI) to Buy
-
Maxim Group Downgrades Stamps.com (STMP) to Hold
-
Adial Pharmaceuticals (ADIL) Prices 2.475M Common Share Offering at $3.25/Sh
-
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
-
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
-
Mesoblast (MESO) Has Numerous Catalysts Ahead - Maxim
-
Priority Income Fund, Inc. Prices Offering of Preferred Stock
-
American Resources Corporation Announces Closing of $4.0 Million Public Offering
-
Priority Income Fund, Inc. Launches Preferred Stock Offering
-
MYnd Analytics (MYND) PT Lowered to $4 at Maxim Group
-
American Resources Corp. (AREC) Prices 1M Class A Share Common Offering at $4/Sh; Announces Uplisting to Nasdaq
-
American Resources Corp. Announces Pricing of $4.0 Million Public Offering and Uplisting to Nasdaq
-
Maxim Group Upgrades Super Micro Computer (SMCI) to Buy
-
Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
-
Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
-
Payment Data Systems Announces Closing of $2 Million Registered Direct Offering
-
Maxim Group Starts AzurRx Biopharma (AZRX) at Buy
-
Maxim Group Starts ABM Industries (ABM) at Buy
-
Maxim Group Starts AzurRx Biopharma (AZRX) at Buy
-
VistaGen Therapeutics (VTGN) Should Benefit From Positive Spravato Recommendation - Maxim
-
Incumaker, Inc. Announces Name Change to uBid Holdings, Inc.
-
Incumaker, Inc. Announces Name Change to uBid Holdings, Inc.
-
Maxim Group Downgrades On Deck Capital (ONDK) to Hold
-
Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record
-
Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record
-
Payment Data Systems (PYDS) Announces $2 Million Registered Direct Offering of iCommon Stock
-
Payment Data Systems Announces $2.0 Million Registered Direct Offering of its Common Stock
-
Taronis Technologies (MNGA) Prices 10.8M Share and Warrant Offering at $1.25/Unit
-
Biocept (BIOC) Prices $7.5 Million Underwritten Public Offering of Common Stock and Warrants
-
Taronis Technologies Announces Pricing of $13.5 Million Underwritten Public Offering
-
Taronis Technologies Announces Pricing of $13.5 Million Underwritten Public Offering
-
Biocept Announces Pricing of $7.5 Million Underwritten Public Offering
-
UPDATE: Taronis Technologies (MNGA) Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants
-
Taronis Technologies Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
Taronis Technologies Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
Applied DNA Reports Fiscal First Quarter 2019 Financial Results
-
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
-
Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
-
Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
-
Maxim Group LLC Expands Healthcare Banking Platform with the Appointment of a Senior Healthcare Banker
-
Maxim Group Downgrades Vertex (VRTX) to Hold
-
Maxim Group Starts ReNeuron Group (RENE:LN) (RNUGF) at Buy
-
BioLineRx (BLRX) Prices $15.4 Million Offering of its American Depositary Shares and Warrants
-
BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
-
Maxim Group Starts TuanChe Ltd. (TC) at Buy
-
Co-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering
-
Milestone Scientific (MLSS) Prices $2M Offering of Common Stock and Warrants
-
Milestone Scientific Announces Pricing of $2.0 Million Offering of Common Stock and Warrants
-
Milestone Scientific Announces Pricing of $2.0 Million Offering of Common Stock and Warrants

